el Pais
http://elpais.com
スイスの製薬会社のROCHE社は、薬の未払いが700日以上の遅延のスペインの12の病院に、薬(特に抗癌剤)の提供を中止すると発表
Roche endurece el suministro a los 12 hospitales más morosos
La firma farmacéutica fija límites de crédito a partir de los cuales deja de fiar
Jaime Prats Valencia27 MAY 2012 - 19:24 CET
Roche hardens supplies to 12 hospitals more delinquent
The pharmaceutical firm fixed credit limits from which makes reliable
Jaime Prats Valencia 27 MAY 2012 - 19:24 CET
The pharmaceutical firm fixed credit limits from which makes reliable
Jaime Prats Valencia 27 MAY 2012 - 19:24 CET
Much of medical debt (some sources amounted to 20,000 million euros) relates to unpaid invoices for drugs supplied to hospitals. The latest data published by the employers in the sector, Farmaindustria, this figure rose to 6.369 million euros at the end of 2011. Given this scenario, the pharmaceutical company Roche has tightened supply conditions at 12 Spanish centers accumulate a further delay with the Swiss multinational.
The firm has set credit limits to these hospitals as sources allowed the drug company. To exceed a certain bar (always above 700 days of delay in payment), Roche no longer trust most. And in these cases, the company serves its products while the hospital or healthcare administration on which depends the center does not pay and lower the debt.
Roche is one of the leading firms in antitumor products. The backlog of orders without serving in some of these hospitals has resulted in the postponement of cancer treatments a day or two, as has happened in hospitals or Xàtiva Basin (Valencia), according to this newspaper have moved to medical sources.
more informationRoche stops working medicines to hospitals in Greece and Spain alertsNovartis warning of the risk that Spain did not pay for their productsRoche fakes with no hospitals to serve delinquent
Chemotherapy sessions are usually scheduled every 14, 21 or 28 days, depending on how aggressive medication, to allow time for the bone to recover. Whenever delays are a day or two "do not in general, major problem," said Emilio Alba, chief of service of the Hospital Virgen de la Victoria in Malaga and president of the Spanish Society of Medical Oncology. A different question is "unrest" which translates to about patients battling a serious illness, "whose effect is even more undesirable from not receiving the medication." Therefore "should not have problems like lack of drugs."
Hospitals affected by what the company calls a "change in business conditions" are four of the Valencian Community, Castilla y León three, three and two of Andalusia Castile-La Mancha. Roche does not detail which hospitals apply these conditions to serve requests for confidentiality reasons. This newspaper has learned from them is the University Hospital Complex of Albacete, Hospital Virgen de la Luz in Cuenca, Lluís Alcanyís of Xativa (Valencia) and the Provincial de Castellón.
The Ministry of Health of Valencia admits "some delay" in payment to Roche. He adds that this problem "will be remedied shortly" after the meetings last week between representatives of the departments of Health and Finance and pharmaceuticals. From the Andalusian Health Service (SAS), with three centers concerned, a spokesman said that the payment status to Roche "is the same as with other providers" (an idea that also include their counterparts Valencia) and remember that SAS is the second customer of the drug company in Spain.
The new delivery rate varies depending on the characteristics of each hospital and depends not only on the debt to drag, but its business model. A particular case (most restrictive) is applied to the Provincial Hospital of Castellón, a consortium of the County Council and the Generalitat. Given its particular legal status, this hospital has its own treasury. This allows Roche to negotiate directly with the hospital and demand that, aside from the debt it has with them, which remains alive and to be recovered-he prepay new orders not to further increase the stock of defaults. Roche maintains these conditions, at least since late last year. Despite having suffered "moments of being overwhelmed," sources close to the hospital's oncology department indicated to this newspaper that "recently" had not suffered supply problems.
Four of the centers are in Valencia
Special case are fully integrated centers on the public. The other hospitals delinquent Valencia, for example, has no direct cash payment or ability, so that agreements are negotiated between Roche and the Ministry of Health. The other three centers Valencian pharmaceutical firm included in this particular blacklist, once exceeding the credit limit, the company gives them new orders only if you pay off part of existing debt by the Government. Whether on account of arrears of the same hospital or from other centers. "This will allow the debt limit we have set will not grow" comment from Roche.
Autonomy with a greater number of hospitals in this situation, Valencia, is the longer it takes to pay to pharmaceutical companies, according to latest data released by the management of laboratories, at the end of last year. By then, the average debt of the Government schools up to 884 days, almost 30% from a year earlier. The default average in Spain in late 2011 was 525 days. Balearic Islands (848), Castile and Leon (816) and Cantabria (804) also exceeded the 800 days.
Roche justifies the measures being implemented by having high exposure to defaults on the public health departments. Between 80% and 90% of its turnover, says the Swiss company, depends on public hospitals. And while one side is optimistic about the provider payment plan agreed between the regions and the Ministry of Finance, which will reset the counter on the debt accumulated by the regions and bring out the invoices that were saved in the drawers until this year, on the other side fears what happens thereafter. "We are very concerned about 2012, there autonomies are not paying."
Shortly after Severin Schwann, CEO of Roche, announced in September last year that his company no longer gave drugs to hospitals in Greece by the accumulation of unpaid bills that threatened to take similar action in Spain, Spanish health authorities are together with the national leaders of the company. The company then feinted with power outages or at least be trusted to leave bills to delinquent centers. The second option is already affecting 12 hospitals.
"We were just 'stock' of antitumor"
Hospital Virgen de la Luz in Cuenca last Friday had 15 days without receiving orders antitumor Roche. "Only used if paid and the Health Service of Castilla-La Mancha is not paying", recounted from the hospital environment.
Among the products to be received was the drug Xeloda (used in treatments for breast, colon or stomach), Herceptin (a monoclonal antibody for breast cancer), Rituximab (lymphoma) and Bevacizumab (breast, colon , lung and ovary). "We have the stock we have and we're running," said a doctor from the center to this day. Last Thursday, we had to ask the hospital in Guadalajara Xeloda because there were no stocks in Cuenca. There were six cancer patients affected, which was delivered late medication.
The situation has reached such a point that from the Health Service of the autonomous community asked of physicians seeking alternative therapies, when this type of cancer drugs do not exist, according to the account of hospital employees. Meanwhile, from the multinational pharmaceutical company moves to workers to pressure their leaders to get paid and thus to serve. The official version is different. "There is no supply problem in any hospital in Castilla-La Mancha nor will be," this newspaper reported a spokeswoman for the Department of Health and Social Affairs.
The hospital's oncology department of Xativa (Valencia) is in a similar situation, with stocks of Roche antineoplastic minimum. "There are drugs that will bring the next day and that not even the doctors know where to go," said a doctor at the center. The workers suspect that are imported from the major hospitals in Valencia: the Clinician, Faith and General. This leads to incidents like the delay of sessions that have to be postponed a day or two. Or cases like that of a patient cited in the morning he refused to leave the hospital to receive their medication. Finally arrived at six o'clock.
The firm has set credit limits to these hospitals as sources allowed the drug company. To exceed a certain bar (always above 700 days of delay in payment), Roche no longer trust most. And in these cases, the company serves its products while the hospital or healthcare administration on which depends the center does not pay and lower the debt.
Roche is one of the leading firms in antitumor products. The backlog of orders without serving in some of these hospitals has resulted in the postponement of cancer treatments a day or two, as has happened in hospitals or Xàtiva Basin (Valencia), according to this newspaper have moved to medical sources.
more informationRoche stops working medicines to hospitals in Greece and Spain alertsNovartis warning of the risk that Spain did not pay for their productsRoche fakes with no hospitals to serve delinquent
Chemotherapy sessions are usually scheduled every 14, 21 or 28 days, depending on how aggressive medication, to allow time for the bone to recover. Whenever delays are a day or two "do not in general, major problem," said Emilio Alba, chief of service of the Hospital Virgen de la Victoria in Malaga and president of the Spanish Society of Medical Oncology. A different question is "unrest" which translates to about patients battling a serious illness, "whose effect is even more undesirable from not receiving the medication." Therefore "should not have problems like lack of drugs."
Hospitals affected by what the company calls a "change in business conditions" are four of the Valencian Community, Castilla y León three, three and two of Andalusia Castile-La Mancha. Roche does not detail which hospitals apply these conditions to serve requests for confidentiality reasons. This newspaper has learned from them is the University Hospital Complex of Albacete, Hospital Virgen de la Luz in Cuenca, Lluís Alcanyís of Xativa (Valencia) and the Provincial de Castellón.
The Ministry of Health of Valencia admits "some delay" in payment to Roche. He adds that this problem "will be remedied shortly" after the meetings last week between representatives of the departments of Health and Finance and pharmaceuticals. From the Andalusian Health Service (SAS), with three centers concerned, a spokesman said that the payment status to Roche "is the same as with other providers" (an idea that also include their counterparts Valencia) and remember that SAS is the second customer of the drug company in Spain.
The new delivery rate varies depending on the characteristics of each hospital and depends not only on the debt to drag, but its business model. A particular case (most restrictive) is applied to the Provincial Hospital of Castellón, a consortium of the County Council and the Generalitat. Given its particular legal status, this hospital has its own treasury. This allows Roche to negotiate directly with the hospital and demand that, aside from the debt it has with them, which remains alive and to be recovered-he prepay new orders not to further increase the stock of defaults. Roche maintains these conditions, at least since late last year. Despite having suffered "moments of being overwhelmed," sources close to the hospital's oncology department indicated to this newspaper that "recently" had not suffered supply problems.
Four of the centers are in Valencia
Special case are fully integrated centers on the public. The other hospitals delinquent Valencia, for example, has no direct cash payment or ability, so that agreements are negotiated between Roche and the Ministry of Health. The other three centers Valencian pharmaceutical firm included in this particular blacklist, once exceeding the credit limit, the company gives them new orders only if you pay off part of existing debt by the Government. Whether on account of arrears of the same hospital or from other centers. "This will allow the debt limit we have set will not grow" comment from Roche.
Autonomy with a greater number of hospitals in this situation, Valencia, is the longer it takes to pay to pharmaceutical companies, according to latest data released by the management of laboratories, at the end of last year. By then, the average debt of the Government schools up to 884 days, almost 30% from a year earlier. The default average in Spain in late 2011 was 525 days. Balearic Islands (848), Castile and Leon (816) and Cantabria (804) also exceeded the 800 days.
Roche justifies the measures being implemented by having high exposure to defaults on the public health departments. Between 80% and 90% of its turnover, says the Swiss company, depends on public hospitals. And while one side is optimistic about the provider payment plan agreed between the regions and the Ministry of Finance, which will reset the counter on the debt accumulated by the regions and bring out the invoices that were saved in the drawers until this year, on the other side fears what happens thereafter. "We are very concerned about 2012, there autonomies are not paying."
Shortly after Severin Schwann, CEO of Roche, announced in September last year that his company no longer gave drugs to hospitals in Greece by the accumulation of unpaid bills that threatened to take similar action in Spain, Spanish health authorities are together with the national leaders of the company. The company then feinted with power outages or at least be trusted to leave bills to delinquent centers. The second option is already affecting 12 hospitals.
"We were just 'stock' of antitumor"
Hospital Virgen de la Luz in Cuenca last Friday had 15 days without receiving orders antitumor Roche. "Only used if paid and the Health Service of Castilla-La Mancha is not paying", recounted from the hospital environment.
Among the products to be received was the drug Xeloda (used in treatments for breast, colon or stomach), Herceptin (a monoclonal antibody for breast cancer), Rituximab (lymphoma) and Bevacizumab (breast, colon , lung and ovary). "We have the stock we have and we're running," said a doctor from the center to this day. Last Thursday, we had to ask the hospital in Guadalajara Xeloda because there were no stocks in Cuenca. There were six cancer patients affected, which was delivered late medication.
The situation has reached such a point that from the Health Service of the autonomous community asked of physicians seeking alternative therapies, when this type of cancer drugs do not exist, according to the account of hospital employees. Meanwhile, from the multinational pharmaceutical company moves to workers to pressure their leaders to get paid and thus to serve. The official version is different. "There is no supply problem in any hospital in Castilla-La Mancha nor will be," this newspaper reported a spokeswoman for the Department of Health and Social Affairs.
The hospital's oncology department of Xativa (Valencia) is in a similar situation, with stocks of Roche antineoplastic minimum. "There are drugs that will bring the next day and that not even the doctors know where to go," said a doctor at the center. The workers suspect that are imported from the major hospitals in Valencia: the Clinician, Faith and General. This leads to incidents like the delay of sessions that have to be postponed a day or two. Or cases like that of a patient cited in the morning he refused to leave the hospital to receive their medication. Finally arrived at six o'clock.
スイスの製薬会社のROCHE社は、薬の未払いが700日以上の遅延のスペインの12の病院に、薬(特に抗癌剤)の提供を中止すると発表
0 件のコメント:
コメントを投稿